# Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

> **NCT00955409** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 160 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** ACC-001(3µg) + QS21
- **BIOLOGICAL:** ACC-001(10µg) + QS21
- **BIOLOGICAL:** ACC-001(30µg) + QS21

## Key facts

- **NCT ID:** NCT00955409
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-05
- **Primary completion:** 2013-12-17
- **Final completion:** 2013-12-17
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2021-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00955409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00955409, "Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00955409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*